Shots: The companies collaborated to assess recombinant protein-based COVID-19 XWG-03, being developed by Innovax with Xiamen University GSK will provide Innovax access to its adjuvant system for preclinical evaluation of the COVID-19 XWG-03. GSK’s adjuvants are additives used in vaccines to boost the body’s immune response to the relevant threat The COVID-19 XWG-03 is based […]Read More
